Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page?

We read with great interest the recent article by Yip et  al., which describes the external validation of PAGE-B related scores for hepatocellular carcinoma (HCC) risk stratification in a very large cohort of patients with chronic hepatitis B treated with nucleo(s)tide analogues (NAs).1 Since it has become clear that NA therapy may reduce but not elimina te the risk of HCC, particularly in patients with cirrhosis, current guidelines recommend continued HCC surveillance despite successful antiviral therapy.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research